Immunology of diabetic and polyglandular neuropathy
1990; Wiley; Volume: 6; Issue: 3 Linguagem: Inglês
10.1002/dmr.5610060304
ISSN1099-0895
Autores Tópico(s)Pain Mechanisms and Treatments
ResumoDiabetes/Metabolism ReviewsVolume 6, Issue 3 p. 169-187 Article Immunology of diabetic and polyglandular neuropathy Steven L. Rabinowe, Steven L. Rabinowe Neuroendocrine Immunology Laboratory, Immunology Section, Joslin Diabetes Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, U.S.A.Search for more papers by this author Steven L. Rabinowe, Steven L. Rabinowe Neuroendocrine Immunology Laboratory, Immunology Section, Joslin Diabetes Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, U.S.A.Search for more papers by this author First published: December 1990 https://doi.org/10.1002/dmr.5610060304Citations: 24AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Bottazzo GF, Florin-Christensen A, and Doniach D: Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine diseases. Lancet ii: 1279–1283, 1974. 10.1016/S0140-6736(74)90140-8 Google Scholar 2 Eisenbarth GS: Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314: 1360–1368, 1986. 10.1056/NEJM198605223142106 CASPubMedWeb of Science®Google Scholar 3 Jackson RA, Morris MA, Haynes BF, and Eisenbarth GS: Increase circulating la-antigen bearing T cells in type I diabetes mellitus. N Engl J Med 306: 785–788, 1982. 10.1056/NEJM198204013061305 CASPubMedWeb of Science®Google Scholar 4 Colman PG, Nayak RC, Campbell IL, and Eisenbarth GS: “Cytoplasmic” islet cell antibodies: evidence that the target antigen is a sialoglycocon-jugate. Diabetes 34: 617–619, 1985. 10.2337/diabetes.34.6.617 PubMedWeb of Science®Google Scholar 5 Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, and Vicari AM: Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318: 1012–1020, 1988. 10.1056/NEJM198804213181602 CASPubMedWeb of Science®Google Scholar 6 Vincent SR, Hokfelt T, Wu J-Y, Elde RP, Morgan LM, and Kimmel JR: Immunohistochemical studies of the GABA system in the pancreas. Neuroendocrinology 36: 197–204, 1983. 10.1159/000123456 CASPubMedWeb of Science®Google Scholar 7 McCleod JG, and Pollard JD: Peripheral neuropathy associated with paraproteinemia. Handb Clin Neurol 51: 429–444, 1987. Google Scholar 8 Ilyas AA, Quarles RH, MacIntosh TD, Doberson MJ, Trapp BD, Dalakas MC, and Brady RO: IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinate in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci USA 81: 1225–1229, 1984. 10.1073/pnas.81.4.1225 CASPubMedWeb of Science®Google Scholar 9 Braun PE, Frail DE, and Latov N: Myelin associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem 39: 1261–1265, 1987. 10.1111/j.1471-4159.1982.tb12563.x Google Scholar 10 Quarles RH, Ilyas AA, and Willison HJ: Antibodies to glycolipids in demyelinating diseases of the human peripheral nervous system. Chem Phys Lipids 42: 235–248, 1986. 10.1016/0009-3084(86)90055-1 CASPubMedWeb of Science®Google Scholar 11 Chou DKH, Ilyas AA, Evans JE, Costello C, Quarles RH, and Jungalwala FB: Structure of sulfated glucuronyl glycolipids in the nervous system reacting with HNK-1 antibody and IgM paraproteins in some neuropathy patients. J Biol Chem 261: 11717–11725, 1986. CASPubMedWeb of Science®Google Scholar 12 Ito H, and Latov N: Monoclonal IgM in two patients with motor neuron disease bind to the carbohydrate antigens Gal(beta 1–3)GalNAc and Gal(beta 1–3)GlcNAc. J Neuroimmunol 19: 245–253, 1988. 10.1016/0165-5728(88)90006-9 CASPubMedWeb of Science®Google Scholar 13 Koski CL, Gratz E, Sutherland J, and Mayer RF: Clinical correlations with anti-peripheral nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol 19: 573–577, 1986. 10.1002/ana.410190609 CASPubMedWeb of Science®Google Scholar 14 Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, Griffin DE, Griffin JW, and McKhann GM: Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 23: 440–447, 1988. 10.1002/ana.410230503 CASPubMedWeb of Science®Google Scholar 15 Koski CL, Chou DKH, and Jungalwala FB: Anti-peripheral nerve myelin antibodies in Guillain-Barré syndrome bind a neutral glycolipid of peripheral myelin and cross-react with Fors-sman antigen. J Clin Invest 84: 280–287, 1989. 10.1172/JCI114152 CASPubMedWeb of Science®Google Scholar 16 Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, Alderson K, and Adams RN: A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24: 73–78, 1988. 10.1002/ana.410240113 CASPubMedWeb of Science®Google Scholar 17 Baba H, Daune GC, Ilyas AA, Pestronk A, Cornblath DR, Chaudry V, Griffin J, and Quarles RH: Anti-GM1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy. J Neuroimmunol 25: 143–150, 1989. 10.1016/0165-5728(89)90131-8 CASPubMedWeb of Science®Google Scholar 18 Daikas MC, and Engel WK: Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 9 (Suppl): 134–135, 1981. 10.1002/ana.410090719 PubMedWeb of Science®Google Scholar 19 vanDoorn PA, Brand A, and Vermeulen M: Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology 37: 1796–1802, 1987. Google Scholar 20 Armati PJ, and Pollard JD: Cytotoxic response of serum from patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Acta Neurol Scand 76: 24–27, 1987. 10.1111/j.1600-0404.1987.tb03539.x CASPubMedWeb of Science®Google Scholar 21 Rizzuto N, and Simonati A: Chronic inflammatory demyelinating polyneuropathy. Int J Tissue React 7: 521–526, 1985. CASPubMedWeb of Science®Google Scholar 22 Hirsch HE, and Parks ME: Serological reactions against glycolipid-sensitized liposomes in multiple sclerosis. Nature 264: 785–787, 1976. 10.1038/264785a0 CASPubMedWeb of Science®Google Scholar 23 Arnon R, Crisp E, Kelley R, Ellison GW, Myers LW, and Tourtellotte WW: Anti-ganglioside anti-bodies in multiple sclerosis. J Neurol Sci 46: 179–186, 1980. 10.1016/0022-510X(80)90076-3 CASPubMedWeb of Science®Google Scholar 24 Endo T, Scott DD, Stewart SS, Kundu SK, and Marcus DM: Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol 132: 1793–1797, 1984. PubMedWeb of Science®Google Scholar 25 Ryberg B: Multiple specificities of antibrain antibodies in multiple sclerosis and chronic myelopathy. J Neurol Sci 38: 357–382, 1978. 10.1016/0022-510X(78)90142-9 CASPubMedWeb of Science®Google Scholar 26 Uhlig H, and Dernick R: Monoclonal autoantibodies derived from multiple sclerosis patients and control persons and their reactivities with antigens of the central nervous system. Autoimmunity 5: 87–99, 1989. 10.3109/08916938909029146 CASPubMedWeb of Science®Google Scholar 27 Emile J, Pouplard A, Bossu van Nieuwenhuyse C, and Bernat-Viallet CL: Maladie de Parkinson, dysautonomie et auto-anticorps dirigés contre les neurones sympathetiques. Rev Neurol (Paris) 136: 221–233, 1980. CASPubMedWeb of Science®Google Scholar 28 Pouplard A, and Emile J: Autoimmunity in Parkinson's disease. Adv Neurol 40: 307–312, 1984. CASPubMedGoogle Scholar 29 Brown FM, Freeman R, Tyler HR, Watts M, Smith AM, and Rabinowe SL: Polyneuroendocrine autoimmunity and Parkinson's disease. Clin Res (Abstr) 37: 356A, 1989. Google Scholar 30 Hirano T, Hashimoto H, and Shiokawa Y: Anti-glycolipid autoantibody detected in the sera from systemic lupus erythematosis patients. J Clin Invest 66: 1437–1440, 1980. 10.1172/JCI109999 CASPubMedWeb of Science®Google Scholar 31 Graf RJ, Halter JB, Halar E, and Porte D Jr.: Nerve conduction abnormalities in untreated maturity onset diabetes: relation to levels of fasting plasma glucose and glycosylated hemoglobin. Ann Intern Med 90: 298–303, 1979. 10.7326/0003-4819-90-3-298 CASPubMedWeb of Science®Google Scholar 32 Gregersen G: Diabetic neuropathy: influence of age, sex, metabolic control and duration of diabetes on motor conduction velocity. Neurology 17: 972–980, 1967. 10.1212/WNL.17.10.972 CASPubMedWeb of Science®Google Scholar 33 Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, Palumbo PJ, and Swanson CJ: Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 8: 590–596, 1980. 10.1002/ana.410080608 CASPubMedWeb of Science®Google Scholar 34 Timperley WR, Boulton AJM, Davies-Jones GAB, Jarratt JA, and Ward JD: Small vessel disease in progressive diabetic neuropathy with good metabolic control. J Clin Pathol 38: 1030–1038, 1985. 10.1136/jcp.38.9.1030 CASPubMedWeb of Science®Google Scholar 35 Fagius J, and Jameson S: Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy: a clinical and neurophysiological study. J Neurol Neurosurg Psychiatry 44: 991–1001, 1981. 10.1136/jnnp.44.11.991 CASPubMedWeb of Science®Google Scholar 36 Young RJ, Ewing DJ, and Clarke BF: A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 32: 938–942, 1983. 10.2337/diab.32.10.938 CASPubMedWeb of Science®Google Scholar 37 Zimmerman BR: Aldose reductase inhibitors. In Diabetic Neuropathy, PJ Dyck, PK Thomas, AK Asbury, AI Winegrad, and D Porte, Eds. W. B. Saunders Philadelphia 1987, pp 190–193. Google Scholar 38 Locke S, and Tarsey D: The nervous system and diabetes. In Joslin's Diabetes Mellitus, 12th ed. A Marble, LP Krall, RF Bradley, AR Christlieb, and JS Soeldner, Eds. Lea and Febiger, Philadelphia, 1985, pp 665–685. Google Scholar 39 Eisenbarth GS, Nayak RC, and Rabinowe SL: Type I diabetes as a chronic autoimmune disease. J Diabetic Complications 2: 54–58, 1988. 10.1016/0891-6632(88)90002-5 CASPubMedGoogle Scholar 40 Schwartz M, Sela BA, and Eshhar N: Antibodies to gangliosides and myelin autoantigens are produced in mice following sciatic nerve injury. J Neurochem 38: 1192–1195, 1982. 10.1111/j.1471-4159.1982.tb07890.x CASPubMedWeb of Science®Google Scholar 41 Hakomori S-I: Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem 50: 733–764, 1981. 10.1146/annurev.bi.50.070181.003505 CASPubMedWeb of Science®Google Scholar 42 Brown FM, Kamalesh M, Adri MNS, and Rabinowe SL: Anti-adrenal medullary antibodies in insulin dependent diabetes and patients at high risk of developing insulin dependent diabetes. Diabetes Care 11: 30–33, 1987. 10.2337/diacare.11.1.30 Web of Science®Google Scholar 43 Rabinowe SL, Brown FM, Watts M, Kadrofske MM, and Vinik AI: Anti-sympathetic ganglia antibodies and postural blood pressure in IDDM subjects of varying duration and patients at high risk of developing IDDM. Diabetes Care 12: 1–6, 1989. 10.2337/diacare.12.1.1 PubMedWeb of Science®Google Scholar 44 Rabinowe SL, and Eisenbarth GS: Polyglandular autoimmunity. Adv Intern Med 31: 293–307, 1986. CASPubMedWeb of Science®Google Scholar 45 Neufeld M, Maclaren NK, and Blizzard RM: Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine 60: 355–362, 1981. 10.1097/00005792-198109000-00003 CASPubMedWeb of Science®Google Scholar 46 Pouplard A, and Emile J: Autoimmunity in Parkinson's disease. Adv Neurol 40: 307–313, 1984. CASPubMedGoogle Scholar 47 Vital C, Brechenmacher C, Cardinaud JP, Manier G, Vital A, and Mora B: Acute inflammatory demyelinating polyneuropathy in a diabetic patient: predominance of vesicular disruption in myelin sheaths. Acta Neuropathol (Berlin) 67: 337–340, 1985. 10.1007/BF00687823 CASPubMedWeb of Science®Google Scholar 48 Vital C, Dumas P, Latinville D, Dib M, Vital A, and Brechenmacher C: Relapsing inflammatory demyelinating polyneuropathy in a diabetic patient. Acta Neuropathol (Berlin) 71: 94–99, 1986. 10.1007/BF00687968 CASPubMedWeb of Science®Google Scholar 49 Quarles RH: Antibodies to complex carbohydrates that may mediate neuropathy. PNEI 2: 109–119, 1989. Google Scholar 50 Williams AF: A year in the life of the immunoglobulin superfamily. Immunol Today 8: 298–303, 1987. 10.1016/0167-5699(87)90016-8 CASPubMedWeb of Science®Google Scholar 51 Williams AF, and Barclay NA: The immunoglobulin superfamily domains for cell surface recognition. Annu Rev Immunol 6: 381–405, 1988. 10.1146/annurev.iy.06.040188.002121 CASPubMedWeb of Science®Google Scholar 52 Lai C, Watson JB, Bloom FE, Sutcliffe JG, and Milner RJ: Neural protein 1B236/MAG defines a subgroup of the immunoglobulin superfamily. Immunol Rev 100: 129–151, 1988. 10.1111/j.1600-065X.1987.tb00530.x PubMedWeb of Science®Google Scholar 53 Edelman GM: CAMs and Igs: Cell adhesion and the evolutionary origins of immunity. Immunol Rev 100: 11–45, 1987. 10.1111/j.1600-065X.1987.tb00526.x CASPubMedWeb of Science®Google Scholar 54 Svennerholm L: Chromatographic separation of human brain gangliosides. J Neurochem 10: 613–623, 1963. 10.1111/j.1471-4159.1963.tb08933.x CASPubMedWeb of Science®Google Scholar 55 Kamoshita S, Aron AM, Suzuki K, and Suzuki K: Infantile Niemann-Pick disease. A chemical study with isolation and characterization of membranous cytoplasmic bodies and myelin. Am J Dis Child 117: 379–394, 1969. 10.1001/archpedi.1969.02100030381001 PubMedGoogle Scholar 56 Fong JW, Ledeen RW, Kundu SK, and Brostoff SW: Gangliosides of peripheral nerve myelin. J Neurochem 26: 157–162, 1976. 10.1111/j.1471-4159.1976.tb04451.x CASPubMedWeb of Science®Google Scholar 57 Suzuki K: Formation and turnover of myelin ganglioside. J Neurochem 17: 209–213, 1970. 10.1111/j.1471-4159.1970.tb02202.x CASPubMedWeb of Science®Google Scholar 58 Spitalnik SL, Danley JM, and Uchigata Y: An islet cell specific human monoclonal autoantibody from a patient with type 1 diabetes recognizes a monosialoganglioside. International Research Symposium, “The Immunology of Diabetes”, American Diabetes Association, Woods Hole, MA, 27–30 October 1987. Google Scholar 59 Nayak RC, Omar MAK, Rabizadeh A, Srikanta S, and Eisenbarth GS: Cytoplasmic islet cell antibodies: evidence that the target antigen is a sialoglycoconjugate. Diabetes 34: 617–619, 1985. 10.2337/diabetes.34.6.617 CASPubMedWeb of Science®Google Scholar 60 Colman PG, Nayak RC, Campbell IL, and Eisenbarth GS: Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid extracts. Diabetes 37: 645–652, 1988. 10.2337/diabetes.37.5.645 CASPubMedWeb of Science®Google Scholar 61 Guillain-Barré Study Group: Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35: 1096–1104, 1985. 10.1212/WNL.35.8.1096 PubMedWeb of Science®Google Scholar 62 Kohn LD, Yavin E, Yavin Z, Lacetti P, Vitti P, Grollman E, and Valente W: Autoimmune thyroid disease studied with monoclonal antibodies to the thyrotropin receptor. In Monoclonal Antibodies Probes for the Study of Autoimmunity and Immunodeficiency, BF Haynes, and GS Eisenbarth, Eds. Academic Press, Orlando, FL, 1983, pp 221–258. Google Scholar 63 Drexhage HA, van der Gaag RD, and Wulffraat NM: The multiplicity of stimulating and blocking autoantibodies in relation to thyroid and extrathyroidal tissues. In Baillière's Clinical Immunology and Allergy: Endocrine and Other Organ-Oriented Autoimmune Disorders, D Doniach, and GF Bottazzo, Eds. Baillière Tindall, London, 1987, pp 125–140. Google Scholar 64 Feizi T, and Handler N: Autoantibodies and disease. In Biochemical Aspects of Human Disease, RS Elkeles, and AS Tavill, Eds. Blackwell Scientific, Oxford, 1983, pp 656–692. Google Scholar 65 Yasuda T, Ueno J, and Matuhasu T: Antiglycolipid antibodies in Behcet's disease. In Behcet's Disease: Pathogenetic Mechanism and Clinical Future, G Inaba, Ed. University of Tokyo Press, Tokyo, 1981, pp 413–420. Google Scholar 66 Inaba G, and Aoyama J: Anti-glycolipid anti-bodies in neuro-Behcet's syndrome. In Behcet's Disease: Pathogenetic Mechanism and Clinical Future, G Inaba, Ed. University of Tokyo Press, Tokyo, 1981, pp 145–152. Google Scholar 67 Witkin SS, Sonnabend J, Richards JM, and Purtilo DT: Induction of antibody to asialo GM1 by spermatozoa and its occurrence in the sera of homosexual men with the acquired immune deficiency syndrome (AIDS). Clin Exp Immunol 54: 346–350, 1983. CASPubMedWeb of Science®Google Scholar 68 Brownlee M, Vlassara H, and Cerami A: Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101: 527–537, 1985. 10.7326/0003-4819-101-4-527 PubMedWeb of Science®Google Scholar 69 Vlassara H, Brownlee M, and Cerami A: Excessive nonenzymatic glycosylation of peripheral and central nervous system components in diabetic rats. Diabetes 32: 670–674, 1983. 10.2337/diabetes.32.7.670 CASPubMedWeb of Science®Google Scholar 70 Vlassar H, Brownlee M, and Cerami A: Recognition and uptake of human diabetic peripheral nerve myelin by macrophages. Diabetes 34: 553–557, 1985. 10.2337/diabetes.34.6.553 PubMedWeb of Science®Google Scholar 71 Carson KA, Bossen EH, Hanker JS: Peripheral neuropathy in mouse hereditary diabetes mellitus. Neuropathol Appl Neurobiol 6: 361–374, 1980. 10.1111/j.1365-2990.1980.tb00672.x PubMedWeb of Science®Google Scholar 72 Clements RS Jr.: New trends in the etiopathogenesis of diabetic neuropathy. In Diabetic Complications: Early Diagnosis and Treatment, D Andreani, G Crepaldi, U Di Mario, and G Pozza, Eds. John Wiley, Chichester, 1987, pp 115–122. Google Scholar 73 Takehazn O, Poduslo JF, and Dyck PJ: Increased endoneurial albumin in diabetic polyneuropathy. Neurology 35: 1790–1791. Google Scholar 74 Brownlee M, Vlassara H, and Cerami A: Trapped immunoglobulins on peripheral nerve myelin from patients with diabetes mellitus. Diabetes 35: 999–1003, 1986. 10.2337/diabetes.35.9.999 CASPubMedWeb of Science®Google Scholar 75 Rabinowe SL, Watts M, and Brown FM: Complement fixing autoantibodies to the sympathetic nervous system and sciatic nerve in type I diabetes mellitus. Diabetes Res Clin Practice (XIII Congr Int Diabetes Fed) 5: 55–76, 1988. Google Scholar 76 Gordon EE, Januszko DM, and Kaufman L: A critical survey of stiff-man syndrome. Am J Med 42: 582–599, 1967. 10.1016/0002-9343(67)90057-5 CASPubMedWeb of Science®Google Scholar 77 Moersch FP, and Woltman HW: Progressive fluctuating muscular rigidity and spasm (stiff-man syndrome): report of a case and some observations in 13 other cases. Mayo Clin Proc 31: 421–427, 1956. CASPubMedWeb of Science®Google Scholar 78 Howard FM Jr.: A new and effective drug in the treatment of the “stiff-man” syndrome: preliminary report. Mayo Clin Proc 38: 203–212, 1963. PubMedWeb of Science®Google Scholar 79 Whelan JL: Baclofen in treatment of the “stiff-man” syndrome. Arch Neurol 37: 600–601, 1980. 10.1001/archneur.1980.00500580096024 CASPubMedWeb of Science®Google Scholar 80 Drake ME Jr.: Stiff-man syndrome and dementia. Am J Med 74: 1085–1087, 1983. 10.1016/0002-9343(83)90824-0 PubMedWeb of Science®Google Scholar 81 Stuart FS, Henry M, and Holley HL: The stiff-man syndrome: report of a case. Arthritis Rheum 3: 229–232, 1960. 10.1002/art.1780030305 CASPubMedWeb of Science®Google Scholar 82 George TM, Burke JM, Sobotka PA, Greenberg HS, and Vinik AI: Resolution of stiff-man syndrome with cortisol replacement in a patient with deficiencies of ACTH, growth hormone, and prolactin. N Engl J Med 310: 1511–1513, 1984. 10.1056/NEJM198406073102306 CASPubMedWeb of Science®Google Scholar 83 Cohen L: Stiff-man syndrome: two patients treated with diazepam. J Am Med Assoc 195: 222–224, 1966. CASPubMedWeb of Science®Google Scholar 84 Martinelli P, Pazzaglia P, Montagna P, Coccagna G, Rizuto N, Simonati S, and Lugaresi E: Stiff-man syndrome associated with nocturnal myoclonus and epilepsy. J Neurol Neurosurg Psychiatry 41: 458–462, 1978. 10.1136/jnnp.41.5.458 CASPubMedWeb of Science®Google Scholar 85 Boiardi A, Crenna P, Bussone G, Negri S, and Merati B: Neurological and pharmacological evaluation of a case of stiff-man syndrome. J Neurol 223: 127–133, 1980. 10.1007/BF00313175 CASPubMedWeb of Science®Google Scholar 86 Solimena M, Folli F, Aparisi R, Pozza G, and DeCamilli P: Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322: 1555–1560, 1990. 10.1056/NEJM199005313222202 CASPubMedWeb of Science®Google Scholar 87 Vicari AM, Folli F, Pozza G, Comi GC, Comola M, Canal N, Besana C, Borri A, Tresoldi M, Solimena M, and DeCamilli P: Plasmapheresis in the treatment of stiff man syndrome. N Engl J Med 320: 1499, 1989. 10.1056/NEJM198906013202220 CASPubMedWeb of Science®Google Scholar 88 Harding AE, Thompson PD, Kocen RS, Batcgelor JR, Davey N, and Marsden CD: Plasma exchange and immunosuppression in the stiff man syndrome. Lancet 2: 915, 1989. 10.1016/S0140-6736(89)91568-7 CASPubMedWeb of Science®Google Scholar 89 Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, and Groover RV: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50: 621–637, 1975. CASPubMedWeb of Science®Google Scholar 90 Adams D, Festenstein H, Gibson JD, Hughes RAC, Jaraquemada J, Papasteriadis C, Sachs J, and Thomas PK: HLA antigens in chronic relapsing idiopathic inflammatory polyneuropathy. J Neurol Neurosurg Psychiatry 42: 184–186, 1979. 10.1136/jnnp.42.2.184 CASPubMedWeb of Science®Google Scholar 91 Stewart GJ, Pollard JD, McLeod JG, and Wolnizer CM: HLA antigens in the Landry-Guillain-Barré syndrome and chronic relapsing polyneuritis. Ann Neurol 4: 285–289, 1978. 10.1002/ana.410040317 CASPubMedWeb of Science®Google Scholar 92 Feeney DJ, Pollard JD, McLeod JG, Steward GJ, and Doran TJ: HLA antigens in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 53: 170–172, 1990. 10.1136/jnnp.53.2.170 PubMedWeb of Science®Google Scholar 93 Potz G, and Neundorfer B: Polyradicular neuritis and Hashimoto thyroiditis. J Neurol 210: 283–289, 1975. 10.1007/BF00316529 CASPubMedWeb of Science®Google Scholar 94 Regev I, Bornstein N, Carasso R, and Vardi Y: Acute polyneuropathy combined with myasthenia gravis. Acta Neurol Scand 65: 681–682, 1982. 10.1111/j.1600-0404.1982.tb03122.x CASPubMedWeb of Science®Google Scholar 95 Korn-Lubetzki I, and Abramsky O: Acute and chronic demyelinating inflammatory polyradiculoneuropathy: association with autoimmune diseases and lymphocyte response to human neuritogenic protein. Arch Neurol 43: 604–608, 1986. 10.1001/archneur.1986.00520060066020 CASPubMedWeb of Science®Google Scholar 96 Thomas PK: Inherited neuropathies. Mayo Clin Proc 58: 476–480, 1983. CASPubMedWeb of Science®Google Scholar 97 Dyck PJ, Swanson CJ, Low PA, Bartleson JD, and Lambert EH: Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc 57: 239–246, 1982. CASPubMedWeb of Science®Google Scholar 98 Brown FM, Watts M, and Rabinowe SL: Inheritance of anti-autonomic nervous system autoantibodies in type I diabetes. Diabetes (Abstr) 39: (Suppl 1): 497, 1990. Web of Science®Google Scholar 99 Cadoni A, Zicca A, and Mancardi GL: Schwann cell expression of HLA-DR antigen in peripheral neuropathies. Lancet 2: 1282–1283, 1986. 10.1016/S0140-6736(86)92712-1 PubMedGoogle Scholar 100 Pollard JD, McCombe PA, Baverstock J, Gatenby PA, and McLeod JC: Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 13: 123–134, 1986. 10.1016/0165-5728(86)90059-7 CASPubMedWeb of Science®Google Scholar 101 Mancardi GL, Cadoni A, Zicca A, Schenone A, Tabaton M, DeMartini, and Zaccheo D: HLA-DR Schwann cell reactivity in peripheral neuropathies of different origins. Neurology 38: 848–851, 1988. 10.1212/WNL.38.6.848 CASPubMedWeb of Science®Google Scholar 102 Guy RJC, Richards F, Edmonds ME, and Watkins PJ: Diabetic autonomic neuropathy and iritis: an association suggesting an immunological cause. Br Med J 289: 343–345, 1984. 10.1136/bmj.289.6441.343 CASPubMedWeb of Science®Google Scholar 103 Wong VG, Anderson RR, and McMaster PRB: Endogenous immune uveitis: the role of serum sickness. Arch Ophthalmol 85: 93–102, 1971. 10.1001/archopht.1971.00990050095015 CASPubMedWeb of Science®Google Scholar 104 Howes EL, and McKay DG: Circulating immune complexes. Effects on ocular vascular permeability in the rabbit. Arch Ophthalmol 93: 365–370, 1975. 10.1001/archopht.1975.01010020377013 PubMedWeb of Science®Google Scholar 105 Dernouchamps JP, Vaerman JP, Michiels J, and Masson PL. Immune complexes in the aqueous humor and serum. Am J Ophthalmol 84: 24–31, 1977. 10.1016/0002-9394(77)90319-1 CASPubMedWeb of Science®Google Scholar 106 Duchen LW, Anjorin NA, Watkins PJ, and Mackay JD: Pathology of autonomic neuropathy in diabetes mellitus. Ann Intern Med 92: 301–303, 1980. 10.7326/0003-4819-92-2-301 CASPubMedWeb of Science®Google Scholar 107 Jackson RA, Morris MA, Haynes BF, and Eisenbarth GS: Increased circulating Ia antigen bearing T cells in type I diabetes mellitus. N Engl J Med 306: 785–788, 1982. 10.1056/NEJM198204013061305 CASPubMedWeb of Science®Google Scholar 108 Jackson RA, Haynes BF, Burch WM, Shimizu K, Bowring MA, and Eisenbarth GS: Ia+ T cells in new onset Graves' disease. J Clin Endocrinol Metab 59: 197–190, 1984. 10.1210/jcem-59-2-187 PubMedWeb of Science®Google Scholar 109 Rabinowe SL, Jackson RA, Dluhy RG, and Williams GH: Ia+ T lymphocytes in recently diagnosed idiopathic Addison's disease. Am J Med 77: 597–601, 1984. 10.1016/0002-9343(84)90348-6 CASPubMedWeb of Science®Google Scholar 110 Gilbey SG, Hussain MJ, Watkins PJ, and Vergani D: Cell-mediated immunity and symptomatic diabetic autonomic neuropathy. Diabetic Med 5: 845–848, 1988. 10.1111/j.1464-5491.1988.tb01122.x CASPubMedWeb of Science®Google Scholar 111 Schopfer K, Matter L, and Tenschert R: Anti-glucagon cell and anti-adrenal medullary cell antibodies in islet cell autoantibody positive diabetic children. N Engl J Med 310: 1536–1537, 1984. 10.1056/NEJM198406073102320 CASPubMedWeb of Science®Google Scholar 112 Brown FM, Smith AM, Longway SL, and Rabinowe SL: Adrenal medullitis in type I diabetes mellitus. J Clin Endocrinol Metab 71: 1491–1495, 1990. 10.1210/jcem-71-6-1491 CASPubMedWeb of Science®Google Scholar 113 Smith SH, Brown MH, Rowe D, Callard RE, and Beverley PCL: Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1. Immunology 58: 63–70, 1986. CASPubMedWeb of Science®Google Scholar 114 Brown FM, Zuckerman M, Longway S, and Rabinowe SL: Adrenal medullary fibrosis in IDDM of long duration. Diabetes Care 12: 494–497, 1989. 10.2337/diacare.12.7.494 CASPubMedWeb of Science®Google Scholar 115 Rabinowe SL, Brown FM, Watts M, and Smith AM: Complement fixing antibodies to sympathetic and parasympathetic tissues in IDDM: the autonomic brake index and heart rate variation. Diabetes Care 13: 1084–1088, 1990. 10.2337/diacare.13.10.1084 CASPubMedWeb of Science®Google Scholar 116 Gilbey SG, Guy RJC, Jones H, Vergani D, and Watkins PJ: Diabetes and autonomic neuropathy: an immunologic association? Diabetic Med 3: 241–245, 1986. 10.1111/j.1464-5491.1986.tb00753.x CASPubMedWeb of Science®Google Scholar 117 McCluskey J, McCann VJ, Kay PH, Zilko PJ, Christiansen FT, O'Neill GJ, and Dawkins RL: HLA and complement allotyes in type 1 (insulin-dependent diabetes). Diabetologia 24: 162–165, 1983. 10.1007/BF00250155 CASPubMedWeb of Science®Google Scholar 118 Brown FM, Brink SJ, Freeman R, and Rabinowe SL: Anti-sympathetic nervous system autoantibodies: diminished catecholamines with orthostasis. Diabetes 38: 938–941, 1989. 10.2337/diabetes.38.7.938 CASPubMedWeb of Science®Google Scholar 119 Bergstrom B, Lilja B, Osterlin S, and Sundkvist G: Autonomic neuropathy in type I diabetes: influence of duration and other diabetes complications. Acta Med Scand 222: 147–154, 1987. 10.1111/j.0954-6820.1987.tb10652.x PubMedWeb of Science®Google Scholar 120 Sundkvist G, Lilja B, and Almer L–O: Abnormal diastolic blood pressure and heart rate reactions to tilting in diabetes mellitus. Diabetologia 19: 433–438, 1980. 10.1007/BF00281822 CASPubMedWeb of Science®Google Scholar 121 Ewing DJ, Campbell IW, Murray A, Neilson JMM, and Clarke BF: Immediate heart rate response to standing: simple test for autonomic neuropathy in diabetes. Br Med J 1: 145–147, 1978. 10.1136/bmj.1.6106.145 PubMedWeb of Science®Google Scholar 122 Goncalves E, Brown FM, and Rabinowe SL: Pilot study of immunosuppressive therapy in diabetic neuropathy associated with neuronal auto-antibodies. Diabetes (Abstr) 39 (Suppl 1): 778, 1990. Google Scholar 123 Kennedy WR, Navarro X, Goetz FC, Sutherland DER, and Najarian JS: Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 322: 1031–1037, 1990. 10.1056/NEJM199004123221503 CASPubMedWeb of Science®Google Scholar 124 Sundkvist G, Lind P, Bergstrom B, Lilja B, and Rabinowe SL: Anti-sympathetic and anti-parasympathetic nerve antibodies in autonomic neuropathy. Diabetologia (Abstr) 33: A33, 1990. Google Scholar 125 Groop LC, Bottazzo GF, and Doniach D: Islet cell antibodies identify latent type I diabetes in patients aged 35–75 years at diagnosis. Diabetes 35: 237–241, 1986. CASPubMedWeb of Science®Google Scholar 126 Barbeau A, and Pourcher E: New data on the genetics of Parkinson's disease. Can J Neurol Sci 9: 60–63, 1982. Web of Science®Google Scholar 127 Carmichael SW, Wilson RJ, Brimijoin WS, Melton LJ, Okazaki H, Yaksh TL, Ahlskog JE, Stoddard SL, and Tyce GM: Decreased catecholamines in the adrenal medulla of patients with Parkinsonism. N Engl J Med 318: 254, 1988. 10.1056/NEJM198801283180415 CASPubMedWeb of Science®Google Scholar 128 Case Records of the Massachusetts General Hospital: Case 46–1987. N Engl J Med 317: 1270–1278, 1987. PubMedGoogle Scholar 129 Bannatyne P, Russell P, and Shearman RP: Autoimmune oophoritis: A clinicopathologic assessment of 12 cases. Int J Gynecol Pathol 9: 191–207, 1990. 10.1097/00004347-199007000-00001 CASPubMedWeb of Science®Google Scholar 130 Taylor HC, Meyes D, and Anton AH: Clonidine suppression test for pheochromocytoma: examples of misleading results. J Clin Endocrinol Metab 63: 238–242, 1986. 10.1210/jcem-63-1-238 CASPubMedWeb of Science®Google Scholar 131 Osserman KE, and Genkins G: Studies in myasthenia gravis. Review of a 20 year experience in over 1200 patients. Mt Sinai J Med, NY 38: 497–537, 1971. CASWeb of Science®Google Scholar 132 Almon RR, Andrew CG, and Appel SH: Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science 186: 55–57, 1974. 10.1126/science.186.4158.55 CASPubMedWeb of Science®Google Scholar 133 Appel SH, Almon RR, and Levy N: Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med 293: 760–761, 1975. 10.1056/NEJM197510092931508 CASPubMedWeb of Science®Google Scholar 134 Lindstom JM, Seybold ME, Lennon VA, Whittingham S, and Duane DD: Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates and diagnostic value. Neurology 26: 1054–1059, 1976. 10.1212/WNL.26.11.1054 PubMedWeb of Science®Google Scholar 135 Engel AG, and Arahata K: The membrane attack complex of complement at the endplate in myasthenia gravis. In Myasthenia Gravis: Biology and Treatment, DB Drachman, Ed. Ann NY Acad Sci 505: 326–332, 1987. Web of Science®Google Scholar 136 Roses AD: Myasthenia gravis. In Immunotherapy of Diabetes and Selected Autoimmune Diseases, GS Eisenbarth, Ed. CRC Press, Boca Raton, FL, 1989, pp 189–196. Google Scholar 137 Olanow CW, Wechsler A, and Roses AD: A prospective study of thymectomy and the acetylcholine receptor antibodies in human myasthenia gravis. Ann Surg 196: 113–121, 1982. 10.1097/00000658-198208000-00001 CASPubMedWeb of Science®Google Scholar 138 Olanow CW, Wechsler AS, Sirotkin-Roses M, Stajich J, and Roses AD: Thymectomy as primary therapy in myasthenia gravis. In Myasthenia Gravis: Biology and Treatment, DB Drachman, Ed. Ann NY Acad Sci 505: 595–606, 1987. Web of Science®Google Scholar 139 Johns TR: Long-term corticosteroid treatment of myasthenia gravis. In Myasthenia Gravis: Biology and Treatment, DB Drachman, Ed. Ann NY Acad Sci 505: 569–583, 1987. Google Scholar 140 Mann JD, Johns TR, and Campa JF: Long-term administration of corticosteroids in myasthenia gravis. Neurology 26: 729–740, 1976. 10.1212/WNL.26.8.729 CASPubMedWeb of Science®Google Scholar 141 Matell G: Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. In Myasthenia Gravis: Biology and Treatment, DB Drachman, Ed. Ann NY Acad Sci 505: 588–594, 1987. Web of Science®Google Scholar 142 Schalke B, Kappos L, Kommasch D, Rohrbach E, and Mertens HG: Cyclosporin, a treatment of myasthenia gravis: initial results of a double-blind trial of cyclosporin a versus azathioprine. In Myasthenia Gravis: Biology and Treatment, DB Drachman, Ed. Ann NY Acad Sci 505: 872–875, 1987. Web of Science®Google Scholar 143 Goulon M, Elkharrat D, Gajdos PH, Lokiec F, and Morel F: Preliminary results in myasthenia gravis treated with cyclosporin. In Myasthenia Gravis: Biology and Treatment, DB Drachman, Ed. Ann NY Acad Sci 505: 857–860, 1987. Web of Science®Google Scholar 144 Rooke ED, Eaton LM, Lambert EH, and Hodgson CH: Myasthenia and malignant intrathoracic tumors. Med Clin N Am 44: 977–988, 1960. 10.1016/S0025-7125(16)33984-0 PubMedWeb of Science®Google Scholar 145 Lambert EH, Okihirio M, and Rooke ED: Clinical physiology of the neuromuscular junction. In Muscle, WM Paul, EE Daniel, CM Kay, and G Monockton, Eds. Pergamon Press, Oxford, 1965, p 487. Web of Science®Google Scholar 146 Gutmann L, Crosby TW, Takamori M, and Martin JD: The Eaton-Lambert syndrome and autoimmune disorders. Am J Med 53: 354–356, 1972. 10.1016/0002-9343(72)90179-9 CASPubMedWeb of Science®Google Scholar 147 Norris FH: Neuromuscular transmission in thyroid disease. Ann Intern Med 64: 81–86, 1966. 10.7326/0003-4819-64-1-81 PubMedWeb of Science®Google Scholar 148 Brown JW, Nelson JR, and Hermann C: Sjogren's syndrome with myopathic and myasthenic features. Bull Los Angeles Neurol Soc 33: 9–20, 1968. CASPubMedGoogle Scholar 149 Kissel P, Schmitt J, Duc M, and Duc ML: Myasthenia and thyrotoxicosis. In Muscle Diseases, JN Walton, N Canal, and G Scarlato, Eds. Excerpta Medica Foundation, Amsterdam, 1970, p 464. Google Scholar 150 Vroom FQ, and Engel WK: Non-neoplastic steroid responsive Lambert-Eaton myasthenic syndrome. Neurology (Abstr) 19: 281, 1969. Web of Science®Google Scholar 151 Mori M, and Takamori M: Hyperthyroidism and myasthenia gravis with features of Eaton-Lambert syndrome. Neurology (Minn) 26: 882–887, 1976. 10.1212/WNL.26.9.882 CASPubMedWeb of Science®Google Scholar 152 Oh SJ: The Lambert-Eaton syndrome in ocular myasthenia gravis. Arch Neurol 31: 183–186, 1974. 10.1001/archneur.1974.00490390065006 CASPubMedGoogle Scholar 153 Lang B, Newsom-Davis J, Wray D, and Vincent A: Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 2: 224–226, 1981. 10.1016/S0140-6736(81)90474-8 CASPubMedWeb of Science®Google Scholar 154 Oh SJ, Dwyer DS, and Bradley RJ: Overlap myasthenic syndrome: combined myasthenia gravis and Eaton-Lambert syndrome. Neurology 37: 1411–1414, 1987. 10.1212/WNL.37.8.1411 CASPubMedWeb of Science®Google Scholar 155 Kusunoki S, Tsuji S, Inoue K, Mannen T, and Nagai Y: Combined features of myasthenia gravis and Eaton-Lambert syndrome: anti-ganglioside antibodies in serum. J Neurol Sci 87: 61–66, 1988. 10.1016/0022-510X(88)90054-8 CASPubMedWeb of Science®Google Scholar 156 Kim YI, and Neher E: IgG from patients with Google Scholar Citing Literature Volume6, Issue3December 1990Pages 169-187 ReferencesRelatedInformation
Referência(s)